Loading organizations...
Longwood Fund creates and invests in science-based companies developing novel solutions for significant medical problems. The firm partners with world-class scientific co-founders, offering hands-on support to drive therapies from laboratory to patient application. Longwood often incubates new ventures, taking active operational roles in their development.
Founded in 2010 by Christoph Westphal, Richard Aldrich, and Michelle Dipp, Longwood Fund emerged from the insight that deep industry expertise could accelerate scientific breakthroughs into viable biopharmaceutical companies. Westphal, a seasoned biotech CEO and entrepreneur, along with his co-founders, established a model for creating impactful life science ventures.
Companies fostered by Longwood Fund aim to address unmet medical needs for patients globally. The firm’s vision is to translate innovative science into meaningful applications, striving to improve lives by building enterprises with transformative healthcare solutions. Longwood remains dedicated to fostering biopharmaceutical innovation.
Longwood has 1 tracked investment across 1 company. The latest tracked deal is $100.0M Series B in Flexiv in December 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 30, 2020 | Flexiv | $100.0M Series B | — | BIN YUE, Richard LIM, Meituan, Meta Capital, NEW Hope Group, Plug And Play, Jack MA |
